Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2306, a Proposed Biosimilar of Cosentyx® (Secukinumab)

2022-11-01

合作抗体生物类似药抗体药物偶联物

GUANGZHOU, China I November 01, 2022 I Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase III clinical study for BAT2306, a proposed biosimilar of Cosentyx® (secukinumab). The clinical study is a randomized, double-blind, parallel group, active control study to compare the efficacy and safety of BAT2306 to Cosentyx® in patients with moderate to severe plaque psoriasis.

Secukinumab is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A. In the US, secukinumab is prescribed for the following indications: 1) people 6 years of age and older with moderate to severe plaque psoriasis, 2) people 4 years of age and older with active enthesitis-related arthritis, 3) people 2 years of age and older with active psoriatic arthritis 4) adults with active ankylosing spondylitis, 5) adults with active non-radiographic axial spondyloarthritis and objective signs of inflammation. After the conclusion of the Phase 3 study Bio-Thera plans to request approval for all available indications at the time of filing the BLA/MAA with NMPA, FDA, EMA and other regulatory bodies around the world.

Bio-Thera Solutions is developing several additional biosimilar products for the global market including biosimilar versions of Actemra®, Simponi®, Stelara®, and Nucala®. QLETLI®, a biosimilar to Humira®, and Pobevcy®, a biosimilar to Avastin®, are approved by the NMPA and being commercialized in China.

About Bio-Thera Solutions

Bio-Thera Solutions, Ltd., a leading global biotechnology company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. A leader in next generation antibody discovery and engineering, the company has advanced eight candidates into late-stage clinical trials and has two approved products, QLETLI® and POBEVCY® in China. In addition, the company has multiple promising candidates in early clinical trials and IND-enabling studies, focusing on immuno-oncology, ADC targeted therapies, autoimmune diseases, and other severe and emerging unmet medical needs. For more information, please visit www.bio-thera.com/en/ or follow us on Twitter (@bio_thera_sol) and WeChat (Bio-Thera).

SOURCE: Bio-Thera Solutions

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构